Literature DB >> 2437805

Na+-K+ pump in chronic renal failure.

D Kaji, K Thomas.   

Abstract

This review summarizes the evidence for the defect in Na+-K+ pump in chronic renal failure, considers the role of various factors in causing this defect, and discusses the clinical implications thereof. Intracellular Na is elevated in erythrocytes, leukocytes, and muscle cells from some patients with chronic renal failure (CRF). Recent evidence suggests that this elevation of cell Na may be, in large part, a consequence of decreased number of Na+-K+ pump units per cell. Maintenance dialysis over a period of weeks ameliorates the defect in intracellular Na+, and this improvement is contemporaneous with an increase in the number of Na+-K+ pump sites per cell. In erythrocytes with normal cell Na+, acute hemodialysis increases the rate of Na+ and K+ transport. Many factors such as the presence of retained toxic metabolite or circulating inhibitor in the uremic plasma, or biochemical changes produced by acute hemodialysis, may explain this finding. In cells with high cell Na+, the pump-mediated K+ transport is normalized at the expense of a raised cell Na+. The decreased muscle membrane potential in uremic subjects has been attributed to a decreased activity of Na+-K+ pump. Enzymatic Na+-K+-ATPase activity of the uremic erythrocyte, leukocyte, sarcolemma, and intestines is also decreased. We discuss the role of hormonal abnormalities and circulating inhibitors, which may cause an acute inhibition of the pump and of other factors such as K+ depletion, which may cause more chronic alterations. The implications of alteration of Na+ and K+ pump transport and raised cell Na+ on other non-pump-mediated transport pathways are discussed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437805     DOI: 10.1152/ajprenal.1987.252.5.F785

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle.

Authors:  S Bonilla; I A Goecke; S Bozzo; M Alvo; L Michea; E T Marusic
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

2.  Blockage of the Na-K-ATPase signaling-mediated oxidant amplification loop elongates red blood cell half-life and ameliorates uremic anemia induced by 5/6th PNx in C57BL/6 mice.

Authors:  Jiang Liu; Muhammad Chaudhry; Fang Bai; Justin Chuang; Hibba Chaudhry; Ala-Eddin Yassin Al-Astal; Ying Nie; Vincent Sollars; Komal Sodhi; Paul Seligman; Joseph I Shapiro
Journal:  Am J Physiol Renal Physiol       Date:  2022-04-18

3.  Urea inhibits NaK2Cl cotransport in human erythrocytes.

Authors:  J Lim; C Gasson; D M Kaji
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

4.  Congenital murine polycystic kidney disease. II. Pathogenesis of tubular cyst formation.

Authors:  E D Avner; W E Sweeney; M C Young; D Ellis
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

5.  Abnormal cation transport in uremia. Mechanisms in adipocytes and skeletal muscle from uremic rats.

Authors:  W Druml; R A Kelly; R C May; W E Mitch
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

6.  Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine.

Authors:  A F Perna; D Ingrosso; V Zappia; P Galletti; G Capasso; N G De Santo
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 7.  Laboratory markers of ventricular arrhythmia risk in renal failure.

Authors:  Ioana Mozos
Journal:  Biomed Res Int       Date:  2014-05-26       Impact factor: 3.411

Review 8.  Fluoride Exposure Induces Inhibition of Sodium-and Potassium-Activated Adenosine Triphosphatase (Na+, K+-ATPase) Enzyme Activity: Molecular Mechanisms and Implications for Public Health.

Authors:  Declan Timothy Waugh
Journal:  Int J Environ Res Public Health       Date:  2019-04-21       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.